Moneycontrol PRO
HomeNewsBusinessStocksBuy Procter and Gamble Hygiene and Healthcare; target of Rs 16,500: Motilal Oswal

Buy Procter and Gamble Hygiene and Healthcare; target of Rs 16,500: Motilal Oswal

Motilal Oswal is bullish on Transport Corporation of India recommended buy rating on the stock with a target price of Rs 16,500 in its research report dated May 23, 2022.

August 26, 2022 / 09:58 IST
Rama Steel Tubes: Nomura Singapore buys 1 lakh shares in Rama Steel Tubes. Nomura Singapore bought 1 lakh equity shares in the company via open market transactions on June 15. These shares were acquired at an average price of Rs 371 per share.

Rama Steel Tubes: Nomura Singapore buys 1 lakh shares in Rama Steel Tubes. Nomura Singapore bought 1 lakh equity shares in the company via open market transactions on June 15. These shares were acquired at an average price of Rs 371 per share.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Motilal Oswal's research report on Procter and Gamble Hygiene and Healthcare

While the sales decline of 3.7% YoY in 4QFY22 (adjusted for a one-off in other operating income) was optically poor, it was on an unusually high base of Vicks sales in FY21 (24.1%) that may have been especially strong in 4QFY21 given the second wave of Covid-19. Even so, the two-year sales CAGR, which has been in the 12-17% range in the preceding three quarters, stood at only 9.2% in 4QFY22. As a percentage of sales, PGHH’s ad spends declined sharply by 1,190bp YoY to 12.8% from the unusually high levels of 4QFY21. In fact, A&P spends moderated in FY22 to 12.4% of sales v/s 14.1% in FY21, which was when P&G chose to increase its ad spends globally rather than curtail marketing spends amid the pandemic. We believe A&P will continue to decline, reaching the 10-11% of sales level going forward. The company has strong earnings growth potential, led by a healthy revenue growth and gradual normalization of the unusually high ad spends in the aftermath of the pandemic as well as the ongoing material cost pressures.

Outlook

We maintain our BUY rating. PGHH’s best-of-breed structural earnings growth potential and improving RoE deserve premium multiples. We maintain our BUY rating with a TP of INR16,500 (premised on 55x FY24E EPS).

More Info

At 09:52 hrs Procter and Gamble Hygiene and Health Care was quoting at Rs 14,190.00, down Rs 13.75, or 0.10 percent.

It has touched an intraday high of Rs 14,232.35 and an intraday low of Rs 14,100.00.

It was trading with volumes of 149 shares, compared to its thirty day average of 683 shares, a decrease of -78.20 percent.

In the previous trading session, the share closed down 0.07 percent or Rs 9.55 at Rs 14,203.75.

The share touched its 52-week high Rs 16,466.40 and 52-week low Rs 12,751.00 on 17 March, 2022 and 19 May, 2022, respectively.

Currently, it is trading 13.82 percent below its 52-week high and 11.29 percent above its 52-week low.

Market capitalisation stands at Rs 46,061.78 crore.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

P&G Hygiene and Healthcare - 250822 - moti

Broker Research
first published: Aug 26, 2022 09:58 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347